Cargando…

Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer

Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, but the underlying molecular mechanisms are largely unknown. Here, we show that 3-dimensional (3D) chromatin interactions both within and between topologically associating domains (TADs) frequently ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Achinger-Kawecka, Joanna, Valdes-Mora, Fatima, Luu, Phuc-Loi, Giles, Katherine A., Caldon, C. Elizabeth, Qu, Wenjia, Nair, Shalima, Soto, Sebastian, Locke, Warwick J., Yeo-Teh, Nicole S., Gould, Cathryn M., Du, Qian, Smith, Grady C., Ramos, Irene R., Fernandez, Kristine F., Hoon, Dave S., Gee, Julia M. W., Stirzaker, Clare, Clark, Susan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965612/
https://www.ncbi.nlm.nih.gov/pubmed/31949157
http://dx.doi.org/10.1038/s41467-019-14098-x
_version_ 1783488650990845952
author Achinger-Kawecka, Joanna
Valdes-Mora, Fatima
Luu, Phuc-Loi
Giles, Katherine A.
Caldon, C. Elizabeth
Qu, Wenjia
Nair, Shalima
Soto, Sebastian
Locke, Warwick J.
Yeo-Teh, Nicole S.
Gould, Cathryn M.
Du, Qian
Smith, Grady C.
Ramos, Irene R.
Fernandez, Kristine F.
Hoon, Dave S.
Gee, Julia M. W.
Stirzaker, Clare
Clark, Susan J.
author_facet Achinger-Kawecka, Joanna
Valdes-Mora, Fatima
Luu, Phuc-Loi
Giles, Katherine A.
Caldon, C. Elizabeth
Qu, Wenjia
Nair, Shalima
Soto, Sebastian
Locke, Warwick J.
Yeo-Teh, Nicole S.
Gould, Cathryn M.
Du, Qian
Smith, Grady C.
Ramos, Irene R.
Fernandez, Kristine F.
Hoon, Dave S.
Gee, Julia M. W.
Stirzaker, Clare
Clark, Susan J.
author_sort Achinger-Kawecka, Joanna
collection PubMed
description Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, but the underlying molecular mechanisms are largely unknown. Here, we show that 3-dimensional (3D) chromatin interactions both within and between topologically associating domains (TADs) frequently change in ER+ endocrine-resistant breast cancer cells and that the differential interactions are enriched for resistance-associated genetic variants at CTCF-bound anchors. Ectopic chromatin interactions are preferentially enriched at active enhancers and promoters and ER binding sites, and are associated with altered expression of ER-regulated genes, consistent with dynamic remodelling of ER pathways accompanying the development of endocrine resistance. We observe that loss of 3D chromatin interactions often occurs coincidently with hypermethylation and loss of ER binding. Alterations in active A and inactive B chromosomal compartments are also associated with decreased ER binding and atypical interactions and gene expression. Together, our results suggest that 3D epigenome remodelling is a key mechanism underlying endocrine resistance in ER+ breast cancer.
format Online
Article
Text
id pubmed-6965612
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-69656122020-01-22 Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer Achinger-Kawecka, Joanna Valdes-Mora, Fatima Luu, Phuc-Loi Giles, Katherine A. Caldon, C. Elizabeth Qu, Wenjia Nair, Shalima Soto, Sebastian Locke, Warwick J. Yeo-Teh, Nicole S. Gould, Cathryn M. Du, Qian Smith, Grady C. Ramos, Irene R. Fernandez, Kristine F. Hoon, Dave S. Gee, Julia M. W. Stirzaker, Clare Clark, Susan J. Nat Commun Article Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, but the underlying molecular mechanisms are largely unknown. Here, we show that 3-dimensional (3D) chromatin interactions both within and between topologically associating domains (TADs) frequently change in ER+ endocrine-resistant breast cancer cells and that the differential interactions are enriched for resistance-associated genetic variants at CTCF-bound anchors. Ectopic chromatin interactions are preferentially enriched at active enhancers and promoters and ER binding sites, and are associated with altered expression of ER-regulated genes, consistent with dynamic remodelling of ER pathways accompanying the development of endocrine resistance. We observe that loss of 3D chromatin interactions often occurs coincidently with hypermethylation and loss of ER binding. Alterations in active A and inactive B chromosomal compartments are also associated with decreased ER binding and atypical interactions and gene expression. Together, our results suggest that 3D epigenome remodelling is a key mechanism underlying endocrine resistance in ER+ breast cancer. Nature Publishing Group UK 2020-01-16 /pmc/articles/PMC6965612/ /pubmed/31949157 http://dx.doi.org/10.1038/s41467-019-14098-x Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Achinger-Kawecka, Joanna
Valdes-Mora, Fatima
Luu, Phuc-Loi
Giles, Katherine A.
Caldon, C. Elizabeth
Qu, Wenjia
Nair, Shalima
Soto, Sebastian
Locke, Warwick J.
Yeo-Teh, Nicole S.
Gould, Cathryn M.
Du, Qian
Smith, Grady C.
Ramos, Irene R.
Fernandez, Kristine F.
Hoon, Dave S.
Gee, Julia M. W.
Stirzaker, Clare
Clark, Susan J.
Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer
title Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer
title_full Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer
title_fullStr Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer
title_full_unstemmed Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer
title_short Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer
title_sort epigenetic reprogramming at estrogen-receptor binding sites alters 3d chromatin landscape in endocrine-resistant breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965612/
https://www.ncbi.nlm.nih.gov/pubmed/31949157
http://dx.doi.org/10.1038/s41467-019-14098-x
work_keys_str_mv AT achingerkaweckajoanna epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT valdesmorafatima epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT luuphucloi epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT gileskatherinea epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT caldoncelizabeth epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT quwenjia epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT nairshalima epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT sotosebastian epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT lockewarwickj epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT yeotehnicoles epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT gouldcathrynm epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT duqian epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT smithgradyc epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT ramosirener epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT fernandezkristinef epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT hoondaves epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT geejuliamw epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT stirzakerclare epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer
AT clarksusanj epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer